Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration

Código QR

Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration

Lena Rung,1 Monica L&ouml;vestam-Adrian21Department of Ophthalmology, Helsingborg Hospital, Helsingborg, 2Department of Ophthalmology, Lund University, Sk&aring;ne University Hospital, Malm&ouml;, SwedenBackground: The purpose of this study was to evaluate the visual outcome...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rung L, L&ouml;vestam-Adrian M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/79aca22bb5204b1db10fa4db528d364a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes
por: Razi F, et al.
Publicado: (2016)

Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes”
por: Kaya A
Publicado: (2016)

Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration
por: Vottonen P, et al.
Publicado: (2013)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova NP, et al.
Publicado: (2016)

No improvement in injection frequency or in visual outcome over time in two cohorts of patients from the same Swedish county treated for wet age-related macular degeneration
por: Schroeder M, et al.
Publicado: (2017)

Visual/anatomical outcome of diabetic macular edema patients lost to follow-up for more than 1 year
por: Ji Soo Kim, et al.
Publicado: (2021)

Macular dysfunction in drusen maculopathy assessed with multifocal electroretinogram and optical coherence tomography
por: Garcia-Garcia JG, et al.
Publicado: (2013)

Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
por: Yan Lu, et al.
Publicado: (2021)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan H, et al.
Publicado: (2014)

Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
por: Chavan R, et al.
Publicado: (2014)

Follow-up of the Development of Femoral Degeneration Lesions in Broilers
por: Almeida Paz,I. C. L, et al.
Publicado: (2009)

High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration
por: Cengiz Tuerksever, et al.
Publicado: (2021)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
por: Hirakata T, et al.
Publicado: (2016)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy B, et al.
Publicado: (2020)

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population
por: Basheer K, et al.
Publicado: (2015)

Quantification of visual field loss in age-related macular degeneration.
por: Jennifer H Acton, et al.
Publicado: (2012)

Long-term follow-up after vitrectomy to treat idiopathic full-thickness macular holes: visual acuity and macular complications
por: Sakaguchi H, et al.
Publicado: (2012)

Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
por: Karagiannis D, et al.
Publicado: (2017)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
por: Horner F, et al.
Publicado: (2019)

Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes
por: Horner F, et al.
Publicado: (2021)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa AC, et al.
Publicado: (2016)

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population: letter to the editor
por: Stewart MW
Publicado: (2015)

Visual outcome of ranibizumab therapy for neovascular age related macular degeneration in the black population: a report of five cases
por: Roopa Vemala, et al.
Publicado: (2010)

Age-related macular degeneration
por: Querques G, et al.
Publicado: (2011)

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study
por: Rakic JM, et al.
Publicado: (2013)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)

Improving Outcomes for Patients with Age-Related Macular Degeneration and Cataracts: The Importance of Including an Assessment of Activities of Daily Life (ADL)
por: Borkenstein AF, et al.
Publicado: (2021)

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study
por: Sakamoto S, et al.
Publicado: (2018)

Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
por: Yamamoto A, et al.
Publicado: (2013)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou SA, et al.
Publicado: (2017)

Treatment of neovascular age-related macular degeneration in patients with diabetes
por: Michael Cummings, et al.
Publicado: (2008)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum]
por: Nudleman E, et al.
Publicado: (2017)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
por: Cheema MR, et al.
Publicado: (2021)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
por: Azuma K, et al.
Publicado: (2018)

Three-year results of a modified photodynamic therapy procedure (Ironing PDT) for age-related macular degeneration patients with large lesions
por: Otsuji T, et al.
Publicado: (2016)

Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development
por: Agarwal A, et al.
Publicado: (2015)

Improving quality of life in patients with end-stage age-related macular degeneration: focus on miniature ocular implants
por: Singer MA, et al.
Publicado: (2011)

Improved sensitivity of microperimetric outcomes for clinical studies in age-related macular degeneration
por: Yaniv Barkana, et al.
Publicado: (2021)

Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
por: Saragoussi D, et al.
Publicado: (2018)

Outcome of 5-year follow-up in men with negative findings on initial biparametric MRI
por: Karen-Cecilie Kortenbach, et al.
Publicado: (2021)